• +1-646-491-9876
    • +91-20-67278686

    Search

    Drug Overdose - Pipeline Review, H1 2017

    Drug Overdose - Pipeline Review, H1 2017

    • Report Code ID: RW0001709421
    • Category Pharmaceuticals
    • No. of Pages 51
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Drug Overdose - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Pipeline Review, H1 2017, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

    Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology) .
    - The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Drug Overdose - Overview
    Drug Overdose - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Drug Overdose - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Overdose - Companies Involved in Therapeutics Development
    Fab'entech SA
    INSYS Therapeutics Inc
    Klaria Pharma Holding AB
    Opiant Pharmaceuticals Inc
    Ventria Bioscience
    Drug Overdose - Drug Profiles
    FBT-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KL-00514 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    melatonin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naloxone hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naloxone hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naloxone hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naloxone hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Drug Overdose - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Drug Overdose - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VEN-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug Overdose - Dormant Projects
    Drug Overdose - Discontinued Products
    Drug Overdose - Product Development Milestones
    Featured News & Press Releases
    Mar 16, 2017: New Data Presented on Adapt Pharmas Community Use of Narcan Nasal Spray 4 mg to Reverse Opioid-Related Overdose
    Mar 15, 2017: Mucodel Pharma Announces Patent Allowance for Mucodel's Co-Gel Buccal Naloxone (Exonal)
    Mar 09, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listings for Two New NARCAN Nasal Spray Patents
    Feb 28, 2017: Adapt Pharma Marks One-Year Anniversary of NARCAN Nasal Spray (naloxone HCl) 4mg Launch in the U.S.
    Feb 21, 2017: Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray
    Jan 30, 2017: Kroger Pharmacies to Increase Access to Naloxone in North Texas, East Texas and Southeast Texas
    Jan 11, 2017: Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals
    Jan 09, 2017: Opiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN Nasal Spray and Heroin Vaccine Development
    Nov 22, 2016: Adapt Pharma Welcomes U.S. Food and Drug Administration Consumer Update Regarding Opioids
    Oct 27, 2016: Opiant Pharmaceuticals Announces FDA Orange Book Listing for Narcan Nasal Spray Patent
    Oct 06, 2016: FDA Joint Meeting Endorses Commitment to Higher Doses and Broader Access for Naloxone to Help in Fight Against Opioid Overdose
    Oct 05, 2016: Adapt Pharma Announces NARCAN coverage with California Medi-Cal Program
    Oct 03, 2016: Health Canada Approves Adapt Pharmas Naloxone Hydrochloride Nasal Spray to Treat Opioid Overdose
    Sep 20, 2016: Newly Published Study Finds NARCAN Nasal Spray Concentrated Formulation Rapidly Delivers an Effective Naloxone Dose and is Readily Usable by the General Public
    Jul 12, 2016: Adapt Pharma to Launch Program to Raise Awareness, Expand Access and Facilitate Product Experience of NARCAN (Naloxone HCl) Nasal Spray - a new Treatment for Opioid Overdose
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Drug Overdose, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Drug Overdose - Pipeline by Fab'entech SA, H1 2017
    Drug Overdose - Pipeline by INSYS Therapeutics Inc, H1 2017
    Drug Overdose - Pipeline by Klaria Pharma Holding AB, H1 2017
    Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, H1 2017
    Drug Overdose - Pipeline by Ventria Bioscience, H1 2017
    Drug Overdose - Dormant Projects, H1 2017
    Drug Overdose - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Drug Overdose, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Fab'entech SA
    INSYS Therapeutics Inc
    Klaria Pharma Holding AB
    Opiant Pharmaceuticals Inc
    Ventria Bioscience

    Request for Sample

    Report Url http://www.reportsweb.com//drug-overdose-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//drug-overdose-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//drug-overdose-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments